FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “NuCana PLC Receives FDA Fast Track Designation for Acelarin”
NuCana PLC (NASDAQ: NCNA) surged over 26% in premarket trading after the U.S. Food and Drug Administration granted the Fast Track designation to Acelarin.
Currently being evaluated in a Phase III study for the first-line treatment of patients with advanced biliary tract cancer, Acelarin now has both Fast Track and Orphan Drug designations in place en route to full FDA approval.
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.
For more information, please visit: NuCana PLC
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.